Affiliation:
1. Central Research Institute of Epidemiology of Rospotrebnadzor
2. Department of Epidemiology, The National Research Center for Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya of the Ministry of Health of the Russian Federation
3. epartment of Epidemiology, The National Research Center for Epidemiology and Microbiology named after Honorary Academician N. F. Gamaleya of the Ministry of Health of the Russian Federation
Abstract
Hepatitis B is an infectious disease that leads to severe health problems, with the risk of chronicity and death. The World Health Organization (WHO) has shown that about 4.5 million premature deaths from the infection could be prevented by 2030 in low- and middle-income countries through vaccination, diagnostic tests, drugs, and education campaigns. The main goal of the WHO global hepatitis strategy is to reduce new infections by 90 % and deaths by 65 % between 2016 and 2030. The successes of hepatitis B vaccine prophylaxis are the basis for setting the ambitious goal of eliminating the disease in the future. However, to date, many questions about the organization and planning of regional vaccination programs remain unresolved and provoke discussions among specialists around the world, including in Russia. In order to systematize and summarize the scientific literature on prevention, as well as to evaluate its effectiveness, we performed a literature search using the electronic bibliographic resources https://pubmed.ncbi.nlm.nih.gov/ and https://elibrary.ru/ using the key words «hepatitis B» and «vaccine prophylaxis». Analysis of scientific papers allowed us to characterize some manifestations of hepatitis B epidemic process and reveal its modern features in the territory of Russia, including risk groups. Aspects of genetic heterogeneity of HBsAg pathogen circulating in Russian territory as well as in adjoining states are given in details. The organization of vaccine prophylaxis is considered; the used immunobiological preparations are characterized. The results of the work define the role of serological studies in the system of epidemic surveillance for hepatitis B, as well as their significance for formation of adequate tactics of vaccination of the population, including in risk groups.
Publisher
PANORAMA Publishing House
Reference44 articles.
1. WHO: HepatitisВ.Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-bAccessed: 4 September 2021.
2. Nechaev V. V., Solomay T. V., Mihajlov M. I. Viral hepatitis and tuberculosis: problems, prospects of study and prevention. Vestnik Sankt-Peterburgskoj medicinskoj akademii im. I. I. Mechnikova. 2003; 4 (1-2): 164–167. (in Russian)
3. Polyanina A. V., Bystrova T. N. Molecular and epidemiological characteristics of hepatitis B virus in conditions of mass vaccine prophylaxis. MediAl. 2019; 2: 10–39. (In Russ.) DOI: 10.21145/2225‑0026 ‑2019‑2‑10‑39.
4. Chulanov V. P., Semenenko T. A., Karandashova I. V., Komarova S. V., Kostiushev D. S., Suslov A. P., Volchkova E. V. Modern view on the problem of choosing a vaccine against hepatitis B. Jepidemiologija i vakcinoprofilaktika. 2017; 4 (95): 65–72. (in Russian)
5. Shulakova N. I. Itogi massovoj immunizacii protiv gepatita V. Results of mass immunization against hepatitis B. 2016; 6 (279): 49–53. (in Russian)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献